US Patent Issued to Ascentage Pharma (Suzhou), Ascentage Pharma Group on Sept. 29 for "Combinations of Bcl-2/Bcl-xL inhibitors and related uses" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,746,221, issued on Sept. 29, was assigned to Ascentage Pharma (Suzhou) Co. Ltd. (Suzhou, China) and Ascentage Pharma Group Corp Ltd. (Hong Kong).

"Combinations of Bcl-2/Bcl-xL inhibitors and related uses" was invented by Yifan Zhai (Suzhou, China) and Dajun Yang (Suzhou, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to combinations of Compound No. 1 or a pharmaceutically acceptable salt thereof and at least one additional therapeutic agent. The present disclosure also relates to methods of treating or preventing a disease via administering to subjects in need thereof Compound No. 1 or a pharmaceutically acceptable ...